HUP2100456A1 - Szemcsepp készítmény - Google Patents

Szemcsepp készítmény

Info

Publication number
HUP2100456A1
HUP2100456A1 HU2100456A HUP2100456A HUP2100456A1 HU P2100456 A1 HUP2100456 A1 HU P2100456A1 HU 2100456 A HU2100456 A HU 2100456A HU P2100456 A HUP2100456 A HU P2100456A HU P2100456 A1 HUP2100456 A1 HU P2100456A1
Authority
HU
Hungary
Prior art keywords
eye drop
drop formulation
formulation
eye
drop
Prior art date
Application number
HU2100456A
Other languages
English (en)
Inventor
Balogh Gyoergy Tibor Dr
Katona Gabor Dr
Csoka Ildiko Dr
Zupko Istvan Dr
Nagy Zoltan Zsolt Prof
Kiss Huba Dr
Takacs Agnes Dr
Csorba Anita Dr
Original Assignee
Semmelweis Egyetem
Univ Szegedi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Semmelweis Egyetem, Univ Szegedi filed Critical Semmelweis Egyetem
Priority to HU2100456A priority Critical patent/HUP2100456A1/hu
Priority to PCT/HU2022/050090 priority patent/WO2023126636A1/en
Publication of HUP2100456A1 publication Critical patent/HUP2100456A1/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
HU2100456A 2021-12-28 2021-12-28 Szemcsepp készítmény HUP2100456A1 (hu)

Priority Applications (2)

Application Number Priority Date Filing Date Title
HU2100456A HUP2100456A1 (hu) 2021-12-28 2021-12-28 Szemcsepp készítmény
PCT/HU2022/050090 WO2023126636A1 (en) 2021-12-28 2022-12-21 Eye drop formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU2100456A HUP2100456A1 (hu) 2021-12-28 2021-12-28 Szemcsepp készítmény

Publications (1)

Publication Number Publication Date
HUP2100456A1 true HUP2100456A1 (hu) 2023-08-28

Family

ID=89993490

Family Applications (1)

Application Number Title Priority Date Filing Date
HU2100456A HUP2100456A1 (hu) 2021-12-28 2021-12-28 Szemcsepp készítmény

Country Status (2)

Country Link
HU (1) HUP2100456A1 (hu)
WO (1) WO2023126636A1 (hu)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10231244A (ja) * 1997-02-19 1998-09-02 Newtec:Kk 親水性包接複合体及びその製造方法
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
CN101757621B (zh) * 2008-11-28 2012-07-04 天津金耀集团有限公司 一种眼部抗炎的环糊精包合药物组合物
PT2616078T (pt) * 2010-09-16 2020-03-31 Shimoda Biotech Pty Ltd Composições de fulvestrant e métodos de uso
WO2012085671A2 (en) * 2010-12-21 2012-06-28 Omegatri As Antioxidants in fish oil powder and tablets
RU2494757C1 (ru) * 2012-04-12 2013-10-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая фермент дезоксирибонуклеазу, альфа-фетопротеин и глицирризиновую кислоту или ее соли: глицирризинат аммония, или дикалия, или тринатрия
TW201902463A (zh) * 2017-06-05 2019-01-16 瑞典商迪茲林製藥股份有限公司 左旋多巴輸注溶液
WO2019086366A1 (en) * 2017-11-06 2019-05-09 Dermalena Di Calderan Andrea N-acetylcysteine and urea-based formulation for the treatment of dermatological disorders

Also Published As

Publication number Publication date
WO2023126636A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
EP3585393A4 (en) FORMULATIONS FOR EYE TREATMENTS
IL276918A (en) Ophthalmic formulation
GB2568579B (en) Ophthalmic drug compositions
EP3672598A4 (en) OCULAR PHARMACEUTICAL COMPOSITIONS
GB201707462D0 (en) Ocular compositions
IL284688A (en) formulation
GB202007546D0 (en) Formulation
EP3639726A4 (en) SUBJECTIVE IL EXAMINATION SYSTEM
HUP2100456A1 (hu) Szemcsepp készítmény
EP3590478C0 (en) EYE DROPS APPLICATION
GB201913232D0 (en) Aerosolisable formulation
GB201820021D0 (en) Ocular hydrogel compositions
GB2595300B (en) Novel Formulation
GB2595453B (en) Novel Formulation
GB2599912B (en) New formulation
EP3871660A4 (en) EYE DROPS COMPOSITION WITH APTAMIN C AS THE ACTIVE SUBSTANCE
IL307849A (en) Sutorsive formulation
IL308046A (en) Alflizib formulation
GB202108165D0 (en) Formulation
GB202107439D0 (en) Formulation
GB202107203D0 (en) Formulation
GB2587402B (en) Formulation
GB202103970D0 (en) Formulation
GB202102636D0 (en) Formulation
GB202102408D0 (en) Formulation